MX2014014468A - Compuestos triazolo como inhibidores de fosfodiesterasa 10 (pde10). - Google Patents
Compuestos triazolo como inhibidores de fosfodiesterasa 10 (pde10).Info
- Publication number
- MX2014014468A MX2014014468A MX2014014468A MX2014014468A MX2014014468A MX 2014014468 A MX2014014468 A MX 2014014468A MX 2014014468 A MX2014014468 A MX 2014014468A MX 2014014468 A MX2014014468 A MX 2014014468A MX 2014014468 A MX2014014468 A MX 2014014468A
- Authority
- MX
- Mexico
- Prior art keywords
- pde10 inhibitors
- compounds
- triazolo compounds
- triazolo
- pde10
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Addiction (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención proporciona compuestos de las fórmulas (la) y (Ib) (ver Fórmulas) en donde R1, R2, R3 y R4 tienen los significados definidos en la descripción y en las reivindicaciones, y también sales farmacéuticamente aceptables de los mismos. Estos compuestos inhiben la PDE10A y pueden utilizarse como medicamentos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12169954 | 2012-05-30 | ||
PCT/EP2013/060838 WO2013178572A1 (en) | 2012-05-30 | 2013-05-27 | Triazolo compounds as pde10 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2014014468A true MX2014014468A (es) | 2015-02-12 |
Family
ID=48534382
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014014468A MX2014014468A (es) | 2012-05-30 | 2013-05-27 | Compuestos triazolo como inhibidores de fosfodiesterasa 10 (pde10). |
Country Status (21)
Country | Link |
---|---|
US (1) | US9394311B2 (es) |
EP (1) | EP2855455B1 (es) |
JP (1) | JP5992096B2 (es) |
KR (1) | KR101666293B1 (es) |
CN (1) | CN104364249B (es) |
AR (1) | AR091185A1 (es) |
AU (1) | AU2013269800A1 (es) |
BR (1) | BR112014026828A2 (es) |
CA (1) | CA2868240A1 (es) |
CL (1) | CL2014002847A1 (es) |
CO (1) | CO7091174A2 (es) |
CR (1) | CR20140481A (es) |
EA (1) | EA201492069A1 (es) |
IL (1) | IL235829A0 (es) |
MX (1) | MX2014014468A (es) |
PE (1) | PE20142366A1 (es) |
PH (1) | PH12014502294A1 (es) |
SG (1) | SG11201406890YA (es) |
TW (1) | TW201402564A (es) |
WO (1) | WO2013178572A1 (es) |
ZA (1) | ZA201407695B (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150081354A (ko) * | 2012-11-07 | 2015-07-13 | 에프. 호프만-라 로슈 아게 | 트라이아졸로 화합물 |
EP3535258B1 (en) | 2016-11-03 | 2021-11-24 | Bristol-Myers Squibb Company | Substituted bicycle heterocyclic derivatives useful as romk channel inhibitors |
CN109666022B (zh) * | 2017-10-17 | 2021-06-15 | 中国科学院上海药物研究所 | 三氮唑衍生物及其制备方法和用途 |
PE20211001A1 (es) | 2018-02-27 | 2021-06-01 | Incyte Corp | Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b |
JP7391046B2 (ja) | 2018-05-18 | 2023-12-04 | インサイト・コーポレイション | A2a/a2b阻害剤としての縮合ピリミジン誘導体 |
GEP20237560B (en) | 2018-07-05 | 2023-10-25 | Incyte Corp | Fused pyrazine derivatives as a2a / a2b inhibitors |
WO2020094592A1 (en) | 2018-11-06 | 2020-05-14 | H. Lundbeck A/S | Compounds for treating negative symptoms and cognitive impairments |
TW202031250A (zh) | 2018-11-06 | 2020-09-01 | 丹麥商H 朗德貝克公司 | 用於治療負性症狀和認知損傷之pde10a抑制劑 |
TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
MX2022002881A (es) * | 2019-09-25 | 2022-06-08 | Oncoarendi Therapeutics Sa | Proceso para la produccion de 5-(4-((2s,5s)-5-(4-clorobencil)-2-me tilmorfolino)piperidin-1-il)-1h-1,2,4-triazol-3-amina. |
CN113929634A (zh) * | 2021-11-22 | 2022-01-14 | 山西永津集团有限公司 | 一种2,3-二溴喹喔啉的合成方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2744116A (en) * | 1953-12-04 | 1956-05-01 | Purdue Research Foundation | Bis-(aminotriazolyl-)-hydrocarbons |
TWI274750B (en) * | 1999-01-12 | 2007-03-01 | Abbott Gmbh & Co Kg | Triazole compounds showing high affinity to dopamine D3 receptor and pharmaceutical composition comprising the same |
US6887870B1 (en) * | 1999-10-12 | 2005-05-03 | Bristol-Myers Squibb Company | Heterocyclic sodium/proton exchange inhibitors and method |
WO2005012485A2 (en) | 2003-07-31 | 2005-02-10 | Bayer Pharmaceuticals Corporation | Methods for treating diabetes and related disorders using pde10a inhibitors |
EP1885713A1 (en) * | 2005-05-18 | 2008-02-13 | Pfizer Limited | 1, 2, 4 -triazole derivatives as vasopressin antagonists |
JP2009504592A (ja) * | 2005-08-10 | 2009-02-05 | スミスクライン・ビーチャム・コーポレイション | 選択的hm74aアゴニストとしてのキサンチン誘導体 |
WO2008103357A1 (en) * | 2007-02-21 | 2008-08-28 | E. I. Du Pont De Nemours And Company | Fungicidal tricyclic 1,2,4-triazoles |
JP2010528991A (ja) * | 2007-05-21 | 2010-08-26 | エスジーエックス ファーマシューティカルズ、インコーポレイテッド | 複素環式キナーゼ調節因子 |
TWI501965B (zh) * | 2008-06-20 | 2015-10-01 | Lundbeck & Co As H | 作為pde10a酵素抑制劑之新穎苯基咪唑衍生物 |
TWI487705B (zh) * | 2009-12-17 | 2015-06-11 | Lundbeck & Co As H | 作為pde10a酵素抑制劑之雜芳香族芳基三唑衍生物 |
AU2011258217B2 (en) * | 2010-05-26 | 2016-12-15 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
PE20130602A1 (es) * | 2010-08-12 | 2013-05-25 | Boehringer Ingelheim Int | Derivados de 6-cicloalquil-1,5-dihidro-pirazolo(3,4-d)pirimidin-4-onas y su uso como inhibidores de pde9a |
WO2012054366A2 (en) * | 2010-10-21 | 2012-04-26 | Merck Sharp & Dohme Corp. | Substituted amino-triazolyl pde10 inhibitors |
-
2013
- 2013-05-27 EA EA201492069A patent/EA201492069A1/ru unknown
- 2013-05-27 JP JP2015514445A patent/JP5992096B2/ja not_active Expired - Fee Related
- 2013-05-27 CN CN201380027925.9A patent/CN104364249B/zh not_active Expired - Fee Related
- 2013-05-27 EP EP13725360.5A patent/EP2855455B1/en not_active Not-in-force
- 2013-05-27 CA CA2868240A patent/CA2868240A1/en not_active Abandoned
- 2013-05-27 SG SG11201406890YA patent/SG11201406890YA/en unknown
- 2013-05-27 AU AU2013269800A patent/AU2013269800A1/en not_active Abandoned
- 2013-05-27 MX MX2014014468A patent/MX2014014468A/es unknown
- 2013-05-27 BR BR112014026828A patent/BR112014026828A2/pt not_active Application Discontinuation
- 2013-05-27 WO PCT/EP2013/060838 patent/WO2013178572A1/en active Application Filing
- 2013-05-27 PE PE2014001616A patent/PE20142366A1/es not_active Application Discontinuation
- 2013-05-27 KR KR1020147036637A patent/KR101666293B1/ko active IP Right Grant
- 2013-05-28 TW TW102118823A patent/TW201402564A/zh unknown
- 2013-05-29 AR ARP130101863 patent/AR091185A1/es unknown
-
2014
- 2014-09-26 CO CO14213791A patent/CO7091174A2/es unknown
- 2014-10-10 PH PH12014502294A patent/PH12014502294A1/en unknown
- 2014-10-16 CR CR20140481A patent/CR20140481A/es unknown
- 2014-10-22 CL CL2014002847A patent/CL2014002847A1/es unknown
- 2014-10-22 ZA ZA2014/07695A patent/ZA201407695B/en unknown
- 2014-11-20 IL IL235829A patent/IL235829A0/en unknown
- 2014-11-25 US US14/552,837 patent/US9394311B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
PH12014502294A1 (en) | 2014-12-15 |
TW201402564A (zh) | 2014-01-16 |
KR20150027143A (ko) | 2015-03-11 |
EP2855455B1 (en) | 2017-11-08 |
CR20140481A (es) | 2014-11-17 |
JP2015518018A (ja) | 2015-06-25 |
BR112014026828A2 (pt) | 2017-06-27 |
CA2868240A1 (en) | 2013-12-05 |
AR091185A1 (es) | 2015-01-14 |
JP5992096B2 (ja) | 2016-09-14 |
PE20142366A1 (es) | 2015-01-10 |
EA201492069A1 (ru) | 2015-03-31 |
ZA201407695B (en) | 2016-08-31 |
CL2014002847A1 (es) | 2015-01-30 |
KR101666293B1 (ko) | 2016-10-13 |
CO7091174A2 (es) | 2014-10-21 |
CN104364249B (zh) | 2018-04-17 |
WO2013178572A1 (en) | 2013-12-05 |
CN104364249A (zh) | 2015-02-18 |
EP2855455A1 (en) | 2015-04-08 |
IL235829A0 (en) | 2015-02-01 |
AU2013269800A1 (en) | 2014-10-09 |
US9394311B2 (en) | 2016-07-19 |
SG11201406890YA (en) | 2014-11-27 |
US20150148332A1 (en) | 2015-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12014502294A1 (en) | Triazolo compounds as pde10 inhibitors | |
UA108640C2 (uk) | Похідні n-(імідазопіримідин-7-іл)гетероариламідів та їх застосування як інгібіторів pde10a | |
UA108711C2 (uk) | Сполуки триазолопіридину як інгібітори фосфодіестерази pde10a | |
UA108105C2 (ru) | Азотсодержащие гетероарильные соединения | |
MX2014012477A (es) | Inhibidores pirrolopirazona de tanquirasa. | |
MX2012007536A (es) | Derivados de heteroarilo que contienen nitrogeno. | |
PH12015500064B1 (en) | Imidazotriazinecarbonitriles useful as kinase inhibitors | |
MX338515B (es) | Derivados de tetrahidroquinolina utiles como inhibidores de bromodominio. | |
PH12014501488A1 (en) | New indolizine derivatives, method for preparing same and pharmaceutical compositions containing same | |
MX336381B (es) | Boronatos como inhibidores de arginasa. | |
MX2013008212A (es) | Derivados de 7-azaindol. | |
MY170878A (en) | [1,2,3] triazolo [4,5-d] pyrimidine derivatives as agonists of the cannabinoid receptor 2 | |
MY191628A (en) | Novel triazolo[4,5-d]pyrimidine derivatives | |
MX2014014832A (es) | Pirrolopirimidona y pirrolopiridona, inhibidores de tanquirasa. | |
MX340607B (es) | Moduladores de la fosfodiesterasa 10 (pde 10). | |
MY186599A (en) | Substituted pyridopyrazines as novel syk inhibitors | |
JO3115B1 (ar) | مركبات بيريدازينون واستخدامها كمثبطات daao | |
UA109037C2 (uk) | Триазолопіридини | |
MX2021005172A (es) | Compuestos de union a nhe3 (intercambiador de sodio-hidrogeno 3) y metodos para inhibir el transporte de fosfato. | |
MX346248B (es) | Derivados de [1,2,3]triazol[4,5-d]pirimidina como agonistas de los agonistas del receptor canabinoide 2. | |
GB201209587D0 (en) | Therapeutic compounds | |
PH12015501175A1 (en) | Substituted pyridopyrazines as syk inhibitors | |
MX2014008864A (es) | Derivados de triazolo[4,5-d]pirimidina. | |
MX2014014308A (es) | Pirrolidino heterociclos. | |
PH12015500399A1 (en) | Azaindolines |